ROKIT Healthcare’s bioprinting-based diabetic foot treatment kit registered as a U.S. FDA medical device

RAPID

Share this Article

ROKIT Healthcare has completed registration of its Dr. INVIVO-based diabetic foot treatment with the U.S. FDA and has successfully completed clinical studies in the U.S.

Since 2019, the company has conducted clinical studies in India, Korea and Turkey, and based on the most recent study results in the U.S., the treatment has shown promising results in all of the study patients with no side effects.

The company reported that the study subjects were patients of chronic diabetic foot ulcer with an average of 64.4 years of age, 15 years of diabetes duration, and obesity in 90% of the patients.

The principal investigator behind the study is Dr. David G. Armstrong, PhD, DPM, who is Professor of Clinical Surgery at University of Southern California and has produced more than 510 peer-reviewed research papers in scholarly medical journals and 90 book chapters with expertise in the treatment and clinical care of the diabetic foot. Dr. Armstrong is past Chair of Scientific Sessions for the American Diabetes Association’s Foot Care Council and the founder and co-chair of the International Diabetic Foot Conference, the largest annual international symposium on the diabetic foot in the world.

“There is no existing method that resolves chronic diabetic foot ulcers by way of true regenerative medicine, especially for those ulcers that failed to close for many months,” said an official of ROKIT Healthcare. “We have seen our bioprinting-based diabetic foot ulcer treatment offer hope for patients who recovered and got back on their feet within just a few weeks after one procedure, making daily life possible again.

“The clinical study results have demonstrated that ROKIT Healthcare’s diabetic foot ulcer treatment kit can effectively regenerate skin of diabetic foot affected areas regardless of various variables such as race, age, and underlying disease. I can take one more step,” he said.

ROKIT Healthcare’s diabetic foot ulcer treatment, which consists of the printer Dr. INVIVO DFU and patient-specific autologous solution extraction kits, uses 3D scanning and AI-based interpretation of patient wounds to create customized skin regeneration patches.

“Given the FDA medical device registration and several successful global studies yielding promising results, we are proud to be leading a meaningful work of saving human lives with cutting-edge regenerative medicine technologies,” said Seok-Hwan You, CEO of ROKIT Healthcare. “I look forward to contributing to the advancement of chronic ulcer treatment methods and significantly improving the quality of life for patients.”

Share this Article


Recent News

Metal Engine Nozzle 3D Printed for Intuitive Machines’ Lunar Mission

Will Stratasys Merge with HP? – Dream Mergers and Acquisitions



Categories

3D Design

3D Printed Art

3D Printed Food

3D Printed Guns


You May Also Like

Aniwaa Unveils 2024 3D Printing Landscape

France’s leading additive manufacturing (AM) marketplace, Aniwaa, released the 2024 version of its AM hardware map, showing 614 3D printer makers and their technologies. Incorporating over 100 updates based on...

3D Printing Webinar and Event Roundup: June 9, 2024

It’s another busy week of 3D printing events, with a few webinars thrown in the mix as well! Advanced Manufacturing for Defense by IDGA, in collaboration with ASTM International, is...

Sponsored

At the Nexus of Global 3D Printing: TCT 3Sixty Launches in UK alongside Med-Tech

Leading UK 3D printing event TCT 3Sixty is back and promises to be another must-see event for the region. Taking place alongside Med-Tech Innovation Expo, the UK and Ireland’s leading...

3D Printing Webinar and Event Roundup: June 2, 2024

Things are heating up in the AM industry, with lots of webinars and events coming this week! Stratasys continues its training courses and road trip, and some major industry events...